We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ranibizumab for the Inhibition of Neovascularization in Pterygia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00768963
First Posted: October 8, 2008
Last Update Posted: July 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sonia Yoo, University of Miami
  Purpose
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Condition Intervention Phase
Pterygium Drug: ranibizumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ranibizumab for the Inhibition of Neovascularization in Pterygia

Resource links provided by NLM:


Further study details as provided by Sonia Yoo, University of Miami:

Primary Outcome Measures:
  • The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • This study aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection and determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence. [ Time Frame: 2 years ]

Enrollment: 10
Study Start Date: October 2008
Study Completion Date: January 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patients will receive one injection of ranibizumab 3 days prior to surgery
Drug: ranibizumab
0.5 mg subconjunctival ranibizumab 3 days prior to surgery
Other Name: Lucentis
Experimental: 2
Patients will undergo one injection of ranibizumab at the time of surgery
Drug: ranibizumab
0.5 mg subconjunctival ranibizumab at the time of surgery
Other Name: Lucentis

Detailed Description:
As a secondary objective, this study also aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection in patients undergoing pterygium excision and to determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will be eligible if the following criteria are met:
  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Patient related considerations: All patients of both genders will be considered for enrollment.
  • Disease related considerations:

    • Patients with pterygia will be considered for enrollment if the pterygium meets standard pterygium excision criteria including encroachment into the visual axis
    • severe induced astigmatism
    • foreign body sensation unresponsive to medical therapy.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from this study:

  • Pregnancy (positive pregnancy test)
  • Women seeking to become pregnant
  • Lactating women
  • Prior enrollment in the study
  • Prior glaucoma surgery in the region of the pterygium
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00768963


Locations
United States, Florida
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Investigators
Principal Investigator: Sonia Yoo, MD Bascom Palmer Eye Institute
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sonia Yoo, Professor, University of Miami
ClinicalTrials.gov Identifier: NCT00768963     History of Changes
Other Study ID Numbers: 20080012
First Submitted: October 7, 2008
First Posted: October 8, 2008
Last Update Posted: July 11, 2017
Last Verified: July 2017

Keywords provided by Sonia Yoo, University of Miami:
ranibizumab
pterygium

Additional relevant MeSH terms:
Neovascularization, Pathologic
Pterygium
Metaplasia
Pathologic Processes
Conjunctival Diseases
Eye Diseases
Ranibizumab
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents